2024: New Small Cell Lung Therapy

On This Day in Health: May 16, 2024

On May 16, 2024, the U.S. Food and Drug Administration granted accelerated approval to tarlatamab, marketed as Imdelltra, for extensive-stage small cell lung cancer that had progressed during or after platinum-based chemotherapy. Small cell lung cancer presents a particularly difficult treatment problem when disease returns after an initial response. The decision introduced a T-cell engager for this setting, giving clinicians another approach for patients whose earlier treatment had stopped controlling the cancer. The approval applied to a specific diagnosis and treatment history. It was not a general authorization for every lung cancer or for everyone starting cancer care.

Tarlatamab is designed to bring two kinds of cells into contact. One part recognizes DLL3, a protein found on the surface of many small cell lung cancer cells. Another engages CD3 on T cells, helping direct an immune response against the cancer. This distinguishes the medicine from conventional chemotherapy and from cellular treatments that require a patient's T cells to be collected and engineered outside the body. It is a manufactured drug administered by a clinical team. Its mechanism illustrates how research can use features of a tumor and the immune system together, while still requiring evidence that the resulting treatment helps people.

The FDA evaluated response evidence from the DeLLphi-301 study, including an efficacy group of 99 patients with previously treated disease. Researchers examined whether tumors shrank and how long responses lasted. Those observations supported the accelerated pathway, which required further confirmation of clinical benefit. They did not establish that every patient would respond or that a response would be permanent. Important risks included cytokine release syndrome and neurologic toxicity. Treatment therefore involved precautions, observation and staff prepared to manage serious reactions. The practical work of delivering the drug safely was part of the new option, alongside the scientific achievement of developing it.

The anniversary captures a change in what could be considered after platinum-based treatment failed. For a person facing that moment, the significance of another option is immediate: it can create a new discussion with the oncology team about goals, expected benefit and the demands of care. For the historical record, the date also marks the movement of T-cell engagement into small cell lung cancer treatment. That progress should be remembered with the conditions attached to the original decision. May 16 recognizes a promising addition to care, the patients who supplied its evidence and the continuing responsibility to establish how well the treatment works over time.